
Standard Member
Ritaglutide (Retatrutide,CAS No.: 2381089-83-2) is a novel GLP-1/GIP/glucagon triple receptor agonist, whose molecular formula has not been disclosed yet. Developed by Lilly, it is currently in Phase III clinical trials for the treatment of type 2 diabetes and obesity. Clinical data show that it has significant hypoglycemic and weight loss effects (up to 24% weight loss in some trials), which may be superior to the existing single/double receptor agonists. As a weekly subcutaneous injection preparation, it regulates metabolism through multiple hormone pathways and is expected to become an important therapy in the field of metabolic diseases. The compound has a patent protection period until the 2030 s and has broad prospects for commercialization.